Original-Research: Gallmetzer HealthCare SpA (von NuWays AG): BUY - T-Online

The issuer is solely responsible for the content of this research. The

invitation to conclude certain stock exchange transactions.

GHC's shares moved to continuous trading. As announced on Friday by the

auctioning to continuous trading procedure effective Nov 2nd. While the

taken to improve accessibility and facilitate ongoing price discovery. It

and allow prices to respond more promptly to new information. Sustained

Operational progress in Intermedical Pharma. Gallmetzer HealthCare has

Qualified Person (QP) at its subsidiary Intermedical Pharma in October 26.

Relevance of the QP to Intermedical Pharma. While adding such a position is

knowledge to GHC at its current developmental stage. The company is expected

which the QP will support with technical expertise. In the future the QP

to the authorities and monitor the hygiene and safety measures.

Production launch expected for H2 27 (eNuW). To recap, the planning phase

for structural and technical measures was completed in February 26.

installations assumed to have been completed in September. Supported by the

the next 7-8 months (eNuW). Production should hence start at the end of

(eNuW) for compliance and quality assurance reasons. First product sales are

to be anticipated for Q4'27 (eNuW). For FY27e, sales at Intermedical Pharma

are seen to already reach EUR 1.9m, in our view.

Total cumulative market revenue potential of EUR 20.5m (eNuW) until FY30e. At

an assumed market product price of c. EUR 28.6 (eNuW) in FY27e, expected to

of the capacity to c. 600k (eNuW) boxes with up to 90% (eNuW) capacity

utilization, Intermedical Pharma is seen as a key growth driver for GHC.

With cumulative EBITDA contributions of EUR 5.7m (eNuW) until FY30 it is also

seen as a key driver of GHC's EBITDA margin outlook.

estimates and confirm BUY at EUR 4.4, based on DCF.

https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=1f09362d1f5c088d6000f4aefb0e8e8e

LinkedIn: https://www.linkedin.com/company/nuwaysag

analysierten Unternehmen befindet sich in der vollständigen Analyse.

Financial/Corporate News and Press Releases.

https://eqs-news.com/?origin_id=4c220339-d68d-11f1-b46d-066675bb9927&lang=en

Die Ströer Digital Publishing GmbH übernimmt keine Gewähr für die Richtigkeit, Genauigkeit und Vollständigkeit der Angaben. Verzögerung der Kursdaten: Deutsche Börse 15 Min., Nasdaq und NYSE 20 Min.